11 results on '"Polo, Susana Vives"'
Search Results
2. POSTER: AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
3. AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
4. AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
5. AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study
6. S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
7. Poster: AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
8. Poster: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
9. Oral Abstract: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
10. AML-468 Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: “Real-Life” Data Versus the RATIFY Study
11. Poster: AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.